

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Timothy L. Macdonald

Title:

FELBAMATE DERIVED COMPOUNDS

Docket No.:

Filed:

1036.031US3

December 17, 2001

Serial No.: 10/023,059 Due Date: September 5, 2002

Group Art Unit: 1614

Examiner:

Commissioner for Patents Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

A return postcard.

 $\frac{\mathbf{X}}{\mathbf{X}}$ A Supplemental Information Disclosure Statement (2 pgs.), Form 1449 (1 pg.), copy of 1 cited reference, and subject search report.

Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

Atty: Robert J. Harris, Ph.D.

Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this 5th day of September, 2002.

**Customer Number 21186** 

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

(GENERAL)

S/N 10/023,059

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

plicant:

Timothy L. Macdonald

RECEIVED

GEP 1 2 2002

TECH CENTER 16001290 Examiner: Unknown Group Art Unit: 1614

SEP 1 1 2002 Seg al No.:

10/023,059

December 17, 2001

Docket: 1036.031US3

FELBAMATE DERIVED COMPOUNDS

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

**Assistant Commissioner for Patents** Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(1) and 37 C.F.R. §1.97(e)(1), Applicant states that each item of information contained in the Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Supplemental Information Disclosure Statement.

It is believed that no fee or statement is required with the Supplemental Information Disclosure Statement.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Serial Number: 10/023,059 Filing Date: December 17, 2001

Title: FELBAMATE DERIVED COMPOUNDS

Page 2 Dkt: 1036.031US3

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

TIMOTHY L. MACDONALD

By his Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938

Minneapolis, MN 55402

(612) 359-3265

Date 7-5-6

Robert J. Harris, Ph.D.

Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 5th day of September, 2002.

Mame

Signature